Molecular docking reveals strong anti-inflammatory and antioxidant potential in bioactive compounds from Simarouba glauca, highlighting therapeutic applications.
Simarouba glauca ( S. glauca ) leaf extract is a rich source of bioactive phytochemicals that have potential therapeutic applications. In this study, we investigated the anti-inflammatory and antioxidant properties of these phytochemicals using in silico molecular docking and pharmacokinetic analyses. High-Resolution Liquid Chromatography-Mass Spectrometry was previously employed for phytochemical profiling, and key compounds were selected for molecular docking studies targeting inflammation-associated enzymes Cyclooxygenase-2 (COX-2) and 5-Lipoxygenase (LOX-5) as well as antioxidant enzymes Superoxide Dismutase (SOD) and Glutathione Peroxidase (GPx). Among the compounds tested, cynaroside exhibited the strongest binding affinity with COX-2 − 10.7 kcal/mol), surpassing the standard drug diclofenac. Similarly, fisetin and robinetin demonstrated high binding affinities with LOX-5 (− 9.5 kcal/mol). In antioxidant studies, flavonoids such as juglanin, kuromanin, and reynoutrin demonstrated higher interactions with SOD (− 7.2 kcal/mol), while cynaroside strongly interacted with GPx (− 7.3 kcal/mol), outperforming ascorbic acid as the control. Pharmacokinetic evaluations revealed favourable drug-likeness and bioavailability for key compounds, including fisetin, robinetin, and catechin, with minimal toxicity risks. These findings emphasize the therapeutic potential of S. glauca phytochemicals as anti-inflammatory and antioxidant agents, providing a foundation for the development of novel plant-based therapies. Future in vitro and in vivo studies are essential to validate these results and explore their clinical applications.
No takes yet. Share an insight, caveat, or question.
Aljawobaei et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: